medigraphic.com
Instituto Nacional de Ciencias Médicas y Nutrición Salvador Zubirán

2018, Number 6

<< Back Next >>

Rev Invest Clin 2018; 70 (6)

Diagnostic Utility of [11C]DTBZ Positron Emission Tomography In Clinically Uncertain Parkinsonism: Experience of a Single Tertiary Center

Pérez-Lohman C, Kerik NE, Díaz-Meneses IE, Cervantes-Arriaga A, Rodríguez-Violante M

Language: English
References: 29
Page: 285-290
PDF size: 181.51 Kb.


ABSTRACT

Background: The use of single-photon emission computed tomography and positron emission tomography (PET) has proven to be helpful in differentiating Parkinson’s disease (PD) from other movement disorders with a sensitivity of up to 95%. Objective: The objective of this study was to determine the accuracy of [11C]DTBZ PET imaging in patients with clinically uncertain parkinsonism from a tertiary referral center in Mexico City. Materials and Methods: Patients who underwent [11C]DTBZ PET brain scan due to clinically uncertain parkinsonism where divided into two groups: PD or non-PD. A scan was considered positive when visual assessment revealed a decrease in [11C]DTBZ uptake typical for PD; a scan was considered negative when visual assessment showed no decrease in [11C]DTBZ uptake or showed a decrease in tracer uptake in a non-PD pattern. Sensitivity, specificity, and positive and negative predictive values were calculated using a 2 × 2 table, with a 95% confidence interval. Results: A total of 39 patients were included in the study. 14 PET studies were deemed positive and 25 PET studies were deemed negative; 12 true positives and 23 true negatives were found. This yielded a sensitivity of 92.9% (95% CI, 66.1-99.8), specificity of 92% (95% CI, 74-99), PPV of 86.7% (95% CI, 63.1-96.1), and NPV of 95.8% (95% CI, 79.1-98.4). Conclusions: The [11C]DTBZ PET has an excellent accuracy for differentiating idiopathic PD from other disorders.


REFERENCES

  1. Rizzo G, Copetti M, Arcuti S, et al. Accuracy of clinical diagnosis of parkinson disease: a systematic review and meta-analysis. Neurology. 2016;86:566-76.

  2. Benamer HTS, Patterson J, Grosset DG, et al. Accurate differentiation of parkinsonism and essential tremor using visual assessment of [123I]-FP-CIT SPECT imaging: the [123I]-FP-CIT study group. Mov Disord. 2000;15:503-10.

  3. Wang J, Jiang YP, Liu XD, et al. 99mTc-TRODAT-1 SPECT study in early parkinson’s disease and essential tremor. Acta Neurol Scand. 2005;112:380-5.

  4. Hu XS, Okamura N, Arai H, et al. 18F-fluorodopa PET study of striatal dopamine uptake in the diagnosis of dementia with lewy bodies. Neurology. 2000;55:1575-7.

  5. Gilman S, Koeppe RA, Little R, et al. Striatal monoamine terminals in lewy body dementia and alzheimer’s disease. Ann Neurol. 2004;55:774-80.

  6. Postuma RB, Berg D, Stern M, et al. MDS clinical diagnostic criteria for parkinson’s disease. Mov Disord. 2015;30:1591-601.

  7. Höglinger GU, Respondek G, Stamelou M, et al. Clinical diagnosis of progressive supranuclear palsy: the movement disorder society criteria. Mov Disord. 2017;32:853-64.

  8. Gilman S, Wenning GK, Low PA, et al. Second consensus statement on the diagnosis of multiple system atrophy. Neurology. 2008;71:670-6.

  9. Bhatia KP, Bain P, Bajaj N, et al. Consensus statement on the classification of tremors. From the task force on tremor of the international parkinson and movement disorder society. Mov Disord. 2018;33:75-87.

  10. Merello M, Nouzeilles MI, Arce GP, Leiguarda R. Accuracy of acute levodopa challenge for clinical prediction of sustained long-term levodopa response as a major criterion for idiopathic parkinson’s disease diagnosis. Mov Disord. 2002;17:795-8.

  11. Kahraman D, Eggers C, Schicha H, Timmermann L, Schmidt M. Visual assessment of dopaminergic degeneration pattern in 123I-FP-CIT SPECT differentiates patients with atypical parkinsonian syndromes and idiopathic parkinson’s disease. J Neurol.0 2012;259:251-60.

  12. Otsuka M, Ichiya Y, Kuwabara Y, et al. Differences in the reduced 18F-dopa uptakes of the caudate and the putamen in parkinson’s disease: correlations with the three main symptoms. J Neurol Sci. 1996;136:169-73.

  13. Nurmi E, Ruottinen HM, Bergman J, et al. Rate of progression in parkinson’s disease: a 6-[18F]fluoro-L-dopa PET study. Mov Disord. 2001;16:608-15.

  14. Suwijn SR, van Boheemen CJ, de Haan RJ, et al. The diagnostic accuracy of dopamine transporter SPECT imaging to detect nigrostriatal cell loss in patients with parkinson’s disease or clinically uncertain parkinsonism: a systematic review. EJNMMI Res. 2015;5:12.

  15. Bega D, Gonzalez-Latapi P, Zadikoff C, Spies W, Simuni T. Is there a role for DAT-SPECT imaging in a specialty movement disorders practice? Neurodegener Dis. 2015;15:81-6.

  16. Sadasivan S, Friedman JH. Experience with daTscan at a tertiary referral center. Parkinsonism Relat Disord. 2015;21:42-5.

  17. Graebner AK, Tarsy D, Shih LC, et al. Clinical impact of 123IIoflupane SPECT (DaTscan) in a movement disorder center. Neurodegener Dis. 2017;17:38-43.

  18. Thiriez C, Itti E, Fénelon G, et al. Clinical routine use of dopamine transporter imaging in 516 consecutive patients. J Neurol, 2015;262:909-15.

  19. Isaacson SH, Fisher S, Gupta F, et al. Clinical utility of DaTscan™ imaging in the evaluation of patients with parkinsonism: a US perspective. Expert Rev Neurother. 2017;17:219-25.

  20. Ibrahim N, Kusmirek J, Struck AF, et al. The sensitivity and specificity of F-DOPA PET in a movement disorder clinic. Am J Nucl Med Mol Imaging. 2016;6:102-9.

  21. Eshuis SA, Maguire RP, Leenders KL, Jonkman S, Jager PL. Comparison of FP-CIT SPECT with F-DOPA PET in patients with de novo and advanced parkinson’s disease. Eur J Nucl Med Mol Imaging. 2006;33:200-9.

  22. Eshuis SA, Jager PL, Maguire RP, et al. Direct comparison of FP-CIT SPECT and F-DOPA PET in patients with parkinson’s disease and healthy controls. Eur J Nucl Med Mol Imaging. 2009;36:454-62.

  23. Vander Borght TM, Sima AA, Kilbourn MR, et al. [3H]methoxytetrabenazine: a high specific activity ligand for estimating monoaminergic neuronal integrity. Neuroscience. 1995;68:955-62.

  24. Bohnen NI, Albin RL, Koeppe RA, et al. Positron emission tomography of monoaminergic vesicular binding in aging and Parkinson´s disease. J Cereb Blood Flow Metab. 2006;26: 1198-212.

  25. Kumar A, Mann S, Sossi V, et al. [11C]DTBZ-PET correlates of levodopa responses in asymmetric parkinson’s disease. Brain. 2003;126:2648-55.

  26. Martin WR, Wieler M, Stoessl AJ, Schulzer M. Dihydrotetrabenazine positron emission tomography imaging in early, untreated parkinson’s disease. Ann Neurol. 2008;63:388-94.

  27. Chen MK, Kuwabara H, Zhou Y, et al. VMAT2 and dopamine neuron loss in a primate model f parkinson’s disease. J Neurochem. 2008;105:78-90.

  28. Kilbourn MR, Frey KA, Vander Borght T, Sherman PS. Effects of dopaminergic drug treatments on in vivo radioligand binding to brain vesicular monoamine transporters. Nucl Med Biol. 1996; 23:467-71.

  29. Wile DJ, Dinelle K, Vafai N, et al. A scan without evidence is not evidence of absence: scans without evidence of dopaminergic deficit in a symptomatic leucine-rich repeat kinase 2 mutation carrier. Mov Disord. 2016;31:405-9.




2020     |     www.medigraphic.com